Amedisys

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amedisys reports robust Q4 earnings, eyes growth amidst operational challenges

Amedisys showcases strong financial performance and strategic initiatives for 2023, focusing on growth and operational optimization.
Despite challenges like labor market issues and operational hurdles, the company remains confident in its growth strategies and talent management.
Opportunities in negotiations with payers, talent acquisition, and operational enhancements position Amedisys for continued success and revenue growth.
With a positive outlook for 2023 and a resilient approach to challenges, Amedisys is poised for steady growth and operational improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The High Acuity Care segment includes providing home care recovery for high acuity patients on either a full risk or limited risk basis. The company was founded in 1982 and is headquartered in Baton Rouge, LA.

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Amedisys (AMED) Q2 Earnings Expected to Decline

NEW YORK , June 29, 2023 /PRNewswire/ --  The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Amedisys, Inc. (" Amedisys" or the "Company") (NASDAQ: AMED) stock prior to May 3, 2023 . You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Amedisys  by Option Care Health, Inc. ("Option Care").

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Amedisys, Inc. by Option Care Health, Inc.

Amedisys' (AMED) combination with Optum brings together two organizations committed to offering patients and their families compassionate, value-based comprehensive care.

Amedisys (AMED) to Advance Value-Based Care With Optum Merger

UnitedHealth Group

In healthcare, the latest acquisition brings to mind that old Fred Astaire song lyric: “Won't you change partners and dance with me?” On Monday, as had been reported here, Amedisys, the home health and hospice firm, agreed to be acquired by UnitedHealth's Optum.

UnitedHealth's Amedisys Deal Come as Home Health and Data Cement Care Ecosystems

UnitedHealth Group outbid Option Care's offer to buy home healthcare provider Amedisys.

UnitedHealth Buys Amedisys for $3.3 Billion

The unsolicited offer from UnitedHealth outbid a $2.8 billion deal.

Amedisys Agrees to UnitedHealth Takeover, Scraps Option Care Health Merger

Home health company Amedisys has agreed to a $3.3 billion merger with UnitedHealth Group. The deal calls for the acquisition of Amedisys' outstanding common stock in an all-cash transaction for $101 per share and places Amedisys under the umbrella of UnitedHealth's Optum arm, according to a Monday (June 26) press release.

Amedisys Agrees to $3.3 Billion UnitedHealth Merger

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amedisys, Inc. (NASDAQ: AMED) to Optum for $101.00 per share is fair to Amedisys shareholders. Halper Sadeh encourages Amedisys shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Amedisys and its board of director.

AMED Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amedisys, Inc. Is Fair to Shareholders

The move for the healthcare-service provider is worth $101 a share.

UnitedHealth Agrees All-Cash Deal to Buy Amedisys

Amedisys Inc on Monday agreed to acquired by UnitedHealth Group for $101 per share in cash, and terminated an all-stock deal to be bought by Option Care Health Inc.

Amedisys agrees to UnitedHealth buyout offer, scraps Option Care deal

Option Care Health

Amedisys Inc. AMED, -0.15% disclosed Monday that it has agreed to merge with UnitedHealth Group Inc. UNH, -0.43%, and terminated its merger with Option Care Health Inc. OPCH, +1.47% agreed on in early-May. Under terms of deal with UnitedHealth, each Amedisys share will be converted into the right to receive $101 in cash, which represents as 10.7% premium to Friday's closing price of $91.21.

Amedisys agrees to merge with UnitedHealth, and terminates deal with Option Care Health

BATON ROUGE, La., June 26, 2023 (GLOBE NEWSWIRE) -- Amedisys (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care, and Optum, a diversified health services company, have agreed to combine. The agreement calls for the acquisition of Amedisys's outstanding common stock in an all-cash transaction for $101 per share.

Amedisys and Optum to Combine, Advancing Value-Based Care for Patients

Addus HomeCare

Chemed

DaVita

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE, AMED and ADUS are well poised to gain.

4 Stocks to Hold in a Challenging Outpatient Home Health Industry

Amedisys is a leading healthcare services company dedicated to providing clinically excellent care and support at home. Currently reporting FCF generation and proposing workforce optimization, clinical optimization, and reorganization initiatives to differentiate service offerings, Amedisys appears quite an attractive stock. If the Board recommends the offer from Option Care Health, we may see an increase in the stock price.

Amedisys: Even Without A Bidding War, The Company Appears Undervalued

The growing yet fragmented home health space is moving toward a more consolidated and centralized footing one deal at a time as major players continue snapping up smaller ones, reinventing home health as a consumer-centric product, service and experience, increasingly delivered by major brands.

Optum Bid for Amedisys Shows Ongoing Reinvention of the Private Healthcare Ecosystem

Amedisys (AMED) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Amedisys (AMED): Can Its 15.4% Jump Turn into More Strength?

Optum's new buyout offer is competing with another buyout offer from Option Care Health. This latest offer would be a $3.26 billion all-cash deal.

Why Shares of Amedisys Are Jumping Monday

Amedisys Inc told investors it received an unsolicited $100 per share bid from UnitedHealth Group's Optum unit that may be ‘superior' to a planned merger with Option Care Health, sending its shares higher in early Monday trade. The Baton Rouge, Louisiana-based healthcare company already agreed to merge with Option Care Health in an all-stock transaction in a deal announced on May 3, 2023.

Amedisys rallies on $3.26B unsolicited bid from UnitedHealth's Optum

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Optum offers to combine with Amedisys, a leading provider of home health, hospice and high-acuity care.

Optum Offers To Combine With Amedisys, Advancing Value-Based Care for Patients

Amedisys Inc. AMED, +3.64% disclosed Monday that it had received an unsolicited cash buyout bid for $100 a share from Optum, which the at-home healthcare services company believes could be considered “superior” to the buyout deal already agreed on with Option Care Health Inc. OPCH, +2.99% in early May. Amedisys shares were still inactive in premarket trading while Option Care's stock rallied 4.7%.

Amedisys received unsolicited buyout bid from Optum that could be ‘superior' to deal with Option Care Health

Amedisys Inc said on Monday it had received an unsolicited proposal from UnitedHealth Group's health services company Optum to acquire all of its outstanding shares in an all-cash transaction worth $3.26 billion.

Amedisys gets over $3 billion unsolicited offer from UnitedHealth's Optum

Amedisys Board Determines Optum Proposal Could Reasonably be Expected to Result in a Superior Proposal

Amedisys Announces Receipt of Unsolicited Proposal From Optum

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amedisys, Inc. (NasdaqGS: AMED) to Option Care Health, Inc. ("Option Care") (NasdaqGS: OPCH). Under the terms of the proposed transaction, shareholders of Amedisys will receive 3.0213 shares of Option Care for each share of Amedisys that they own. KSF is seeking to determine whether this consideration and the.

AMEDISYS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amedisys, Inc. - AMED

NEW YORK , May 4, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Amedisys, Inc. (NASDAQ: AMED) and its board of directors concerning the proposed merger of the company with Option Care Health, Inc. (NASDAQ: OPCH). Stockholders will receive 3.0213 shares of Option Care Health common stock for each share of Amedisys stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Merger of Amedisys, Inc.

Amedisys (AMED) sees a year-over-year decline in the Hospice segment's revenues.

News for Amedisys Stock (AMED)